Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...